A Phase 2 Multicenter Study of TL-895 in Subjects with Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Activation Syndrome

Research summary

This is a multicenter Phase 2 study of TL-895 in subjects with MF or ISM. Myelofibrosis (Cohorts 1-4) Treatment for subjects with MF in Cohorts 1-4 will be open-label, with enrollment for each cohort as follows: subjects with R/R MF (Cohort 1), JAKi-intolerant MF (Cohort 2), and MF ineligible for JAKi treatment (Cohort 3 and Cohort 4). Part A will evaluate the safety and tolerability of different doses of TL-895 when administered in different schedules to determine the RP2D for each cohort. Part B will further evaluate the safety and efficacy of TL-895 at the RP2D and schedule determined in Part A.

Principal Investigator

Prof Adam Mead

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1009324